A preliminary investigation has found no evidence directly linking the deaths of four children in Japan with the vaccines the young victims received shortly before they succumbed. But Reuters reports that Japan’s health ministry will continue its suspension on the use of the two vaccines, which are used to prevent meningitis and pneumonia.
The four children, all under two years old, died last week shortly after they were vaccinated with Sanofi’s ActHIB, Pfizer’s Prevenar or both. The health ministry responded by imposing its suspension and launching an investigation into the immunizations.
Sanofi and Pfizer have stood behind their vaccines and some experts have suggested the ministry overreacted. The suspension “was the wrong thing to do,” Paul Offit, a researcher at Children’s Hospital in Philadelphia, told Forbes.com.
The ministry announced its preliminary investigative findings at a hearing Tuesday. Reuters quoted the Kyodo news agency as saying that further studies were needed on the vaccine, and that the suspension would continue.
In the U.S., health agencies “have not detected new safety concerns or unusual reporting patterns” in children given either vaccine, a spokesman for the Food and Drug Administration said.
Related Post:
4 Deaths Spur Suspension of Pfizer, Sanofi Vaccines in Japan


